Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Issue 34 (March 2020)
- Record Type:
- Journal Article
- Title:
- Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Issue 34 (March 2020)
- Main Title:
- Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
- Authors:
- Gautret, Philippe
Lagier, Jean-Christophe
Parola, Philippe
Hoang, Van Thuan
Meddeb, Line
Sevestre, Jacques
Mailhe, Morgane
Doudier, Barbara
Aubry, Camille
Amrane, Sophie
Seng, Piseth
Hocquart, Marie
Eldin, Carole
Finance, Julie
Vieira, Vera Esteves
Tissot-Dupont, Hervé Tissot
Honoré, Stéphane
Stein, Andreas
Million, Matthieu
Colson, Philippe
La Scola, Bernard
Veit, Véronique
Jacquier, Alexis
Deharo, Jean-Claude
Drancourt, Michel
Fournier, Pierre Edouard
Rolain, Jean-Marc
Brouqui, Philippe
Raoult, Didier - Abstract:
- Abstract: Background: We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. Methods: We conducted an uncontrolled, non-comparative, observational study in a cohort of 80 relatively mildly infected inpatients treated with a combination of hydroxychloroquine and azithromycin over a period of at least three days, with three main measurements: clinical outcome, contagiousness as assessed by PCR and culture, and length of stay in infectious disease unit (IDU). Results: All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days. Conclusion: We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.
- Is Part Of:
- Travel medicine and infectious disease. Issue 34(2020)
- Journal:
- Travel medicine and infectious disease
- Issue:
- Issue 34(2020)
- Issue Display:
- Volume 34, Issue 34 (2020)
- Year:
- 2020
- Volume:
- 34
- Issue:
- 34
- Issue Sort Value:
- 2020-0034-0034-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-03
- Subjects:
- COVID-19 -- SARS-CoV-2 -- Hydroxychloroquine -- Azithromycin -- PCR -- Culture
Travel -- Health aspects -- Periodicals
Communicable diseases -- Periodicals
Tropical medicine -- Periodicals
610.5 - Journal URLs:
- http://www.sciencedirect.com/science/journal/14778939 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.tmaid.2020.101663 ↗
- Languages:
- English
- ISSNs:
- 1477-8939
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9045.452675
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13500.xml